# Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

> **NCT04769297** · PHASE4 · UNKNOWN · sponsor: **Limbic Medical** · enrollment: 30 (actual)

## Conditions studied

- Acute Stress Disorder

## Interventions

- **DRUG:** Sublingual Micro-Dose Ketamine

## Key facts

- **NCT ID:** NCT04769297
- **Lead sponsor:** Limbic Medical
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-15
- **Primary completion:** 2021-04
- **Final completion:** 2021-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04769297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04769297, "Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04769297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*